Novo’s One-Hit Wonder Risk
19:53–20:54 · 61s
Lou warns Novo is second to Lilly and risks becoming a one-hit wonder unless it invests profits beyond GLP-1 variants into what's next.
19:53–20:54 · 61s
Lou warns Novo is second to Lilly and risks becoming a one-hit wonder unless it invests profits beyond GLP-1 variants into what's next.
We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.